Allergy & Asthma Network Mothers of Asthmatics (AANMA)

FDA Final Rule on MDI Transition

Published April - 14 - 2010 Print This Post

The Food and Drug Administration (FDA) has announced that seven more metered dose inhalers (MDIs) containing ozone-depleting propellants will be phased out.

Four of the medications have already been discontinued: Tilade, Intal, Azmacort and Alupent; and two of the remaining three have a small market share: Aerobid and MaxAir. Combivent is used by patients with chronic obstructive pulmonary disease (COPD) and by some patients who have both COPD and asthma.

The phase-out dates for each of these can be read here: [^]

We expect that an Aerobid HFA replacement will be approved prior to its phase-out. We expect the same for Combivent.

Visit our website,, for more news and updates from AANMA. Thank you.